No annual revenue total was found in BRIACELL THERAPEUTICS CORP.'s SEC filings.
Briacell Therapeutics Corp. (BCTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$28.8 million.
Revenue
—
Net income
$-34.90M
-32.7% vs prior year
Operating cash flow
$-28.65M
-1.7% vs prior year
Free cash flow
$-28.78M
-17.1% vs prior year
EPS
$-6.97
+88.8% vs prior year
Dividend per share
None
Shares outstanding
8.73M
+363.5% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
- Fiscal year ends
- July 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- West Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1610820
- Former names
- Ansell Capital Corp. (until Jun 20, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jul 31, 2026 |
FY 2025 Jul 31, 2025 |
FY 2024 Jul 31, 2024 |
FY 2023 Jul 31, 2023 |
FY 2022 Jul 31, 2022 |
|---|---|---|---|---|---|
| Operating income | -$36.1M | -$27.2M | -$33.3M | -$23.3M | -$15.3M |
| Net income | -$34.9M | -$26.3M | -$4.8M | -$20.3M | -$26.8M |
| Diluted EPS | -$6.97 | -$62.19 | -$43.68 | -$1.30 | — |
| Operating cash flow | -$28.7M | -$28.2M | -$24.1M | -$23.7M | -$12.5M |
| Free cash flow | -$28.8M | — | -$24.6M | — | — |
| Total assets | $23.6M | $21.6M | $5.9M | $27.2M | $42.6M |
| Stockholders' equity | $15.6M | $17.3M | -$2.7M | — | — |
| Cash and investments | $20.5M | $17.9M | $862,089 | $21.3M | $41.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Oct 28, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2026 | Jun 26, 2026 |
| 10-Q | Quarterly report | Jun 9, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 3, 2026 | May 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 31, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Mar 10, 2026 | Jan 31, 2026 |
All 324 Briacell Therapeutics Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.